GlassScriptPhysician profile
Ella Krouse
NPI 1669963237
$5,453.99
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,654 · 2022: $1,800.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $655.34 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $505.57 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $453.71 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $449.23 | 2021-2022 | |
| Alkermes, INC. | $446.62 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $394.07 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $337.26 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $328.59 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $256.92 | 2021-2022 | |
| Validus Pharmaceuticals LLC | $237.00 | 2021 | |
| Avanir Pharmaceuticals, INC. | $200.84 | 2021-2022 | |
| Eisai INC. | $165.19 | 2021-2022 | |
| Bausch Health US, LLC | $142.18 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $125.29 | 2021 | |
| Merck Sharp & Dohme LLC | $99.21 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $96.62 | 2021-2022 | |
| Lundbeck LLC | $95.90 | 2021-2022 | |
| Almatica Pharma LLC | $89.27 | 2022 | |
| Noven Therapeutics, LLC | $64.81 | 2022 | |
| Uswm, LLC | $61.22 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $47.88 | 2022 | |
| Corium, LLC | $45.54 | 2022 | |
| Sunovion Pharmaceuticals INC. | $33.14 | 2021 | |
| Adlon Therapeutics L.P. | $31.50 | 2021 | |
| Ironshore Pharmaceuticals INC. | $23.02 | 2021 | |
| Supernus Pharmaceuticals, INC. | $22.82 | 2021 | |
| Owp Pharmaceuticals, INC. | $15.54 | 2022 | |
| Gilead Sciences, INC. | $14.99 | 2021 | |
| Neos Therapeutics, LP | $14.72 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ella Krouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.